TABLE 6.

Validation cohort characteristics

	CLAD (n = 22)	Control (n = 17)	P-value
Age at transplant, median (IQR)	54 (44.7–57.6)	60.6 (28.8–66.5)	.94
Female, n (%)	12 (54.5)	7 (41.1)	.61
Transplant diagnosis			.55
Cystic fibrosis, n (%)	3 (13.6)	5 (29.4)
Interstitial lung disease, n (%)	15 (68.2)	10 (58.8)
Chronic obstructive pulmonary disease, n (%)	3 (13.6)	2 (11.8)
Pulmonary hypertension, n (%)	1 (4.5)	0 (0)
Acute rejection, n (%)	7 (31.8)	1 (5.8)	.13
Acute infection, n (%)	11 (50.0)	0	<.01
Bacterial	8	—
Viral	1	—
Fungal	5
Days from Tx to CLAD, median (IQR)	955 (641–1478)
Days from CLAD onset to brush, median (IQR)	6 (1–40)
BOS stage at brush, n (%)
BOS 0p	3 (14)
BOS 1	7 (32)	—
BOS 2	8 (36)	—
BOS 3	4 (18)	—